Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down to $11.19

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares gapped down prior to trading on Monday . The stock had previously closed at $11.19, but opened at $10.96. Pulse Biosciences shares last traded at $11.01, with a volume of 8,485 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Thursday, June 27th.

Pulse Biosciences Price Performance

The firm has a 50-day moving average of $10.23 and a 200-day moving average of $9.57.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter.

Insider Buying and Selling

In other Pulse Biosciences news, CEO Burke Thomas Barrett purchased 10,000 shares of the stock in a transaction on Monday, May 20th. The shares were bought at an average cost of $8.56 per share, with a total value of $85,600.00. Following the completion of the acquisition, the chief executive officer now owns 10,000 shares in the company, valued at $85,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 71.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cetera Advisors LLC acquired a new stake in Pulse Biosciences during the first quarter valued at $109,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Pulse Biosciences during the 1st quarter valued at about $88,000. Vanguard Group Inc. grew its position in shares of Pulse Biosciences by 28.8% during the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after acquiring an additional 189,227 shares during the period. Inspire Investing LLC increased its stake in shares of Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after purchasing an additional 10,039 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Pulse Biosciences by 63.6% in the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares during the period. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.